Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC
Clinical trial NCT03717155 · COMPLETED
Trial details
- NCT number
- NCT03717155
- Sponsor
- Merck KGaA, Darmstadt, Germany
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-30
- Primary completion
- 2020-09-30
- Enrollment
- 43
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.